Male breast cancer. Clinical experience of the Russian Scientific Center of Roentgenradiology of the Ministry of Health of Russia

Abstract

Interest in male breast cancer is increasing every year due to the increase in the spread of this disease. However, the lack of randomized trials in male breast cancer draws the attention of specialists to this problem. Male breast cancer is 100 times less common than female. Over the past decades, there has been an increase in the disease up to 26 %. Low awareness of general practitioners, as well as the male part of the population, untimely access to specialized specialists are the reasons for the late diagnosis of the disease. Recommendations for the treatment of male breast cancer are based on the results of studies conducted in female with a similar diagnosis.In the period from January 2015 to September 2022, 13 patients diagnosed with male breast cancer were examined and treated in the Department of Oncology and Reconstructive Plastic Surgery of the Breast of the Russian Scientific Center of Roentgenradiology, Ministry of Health of Russia. The age of patients at the time of treatment ranged from 58 to 75 years, with a mean age of 63 years. In 2 patients (15 %), stage 0 was established, in 4 (31 %) – stage Ia, in 4 (31 %) – stage IIa, in 1 (7.6 %) – stage IIb, in 1 (7.7 %) – stage IIIb, in 1 (7.6 %) – stage IIIc. Two (15 %) patients underwent neoadjuvant polychemotherapy, 6 (46 %) patients underwent adjuvant polychemotherapy. In 7 (54 %) patients, surgical treatment was performed without further adjuvant polychemotherapy. Six (46 %) patients underwent radiation therapy. Hormone therapy was prescribed to all 13 (100 %) patients. When contacting the clinic, the most frequent complaints would be the appearance of a seal behind the nipple, discharge from the nipple.When diagnosing male breast cancer, the same methods are used as female. Tactics of treatment is determined individually. Early diagnosis of the disease and timely prescribed therapy lead to many years of remission.